Pulmotech MAA market seen growing through 2030

The Business Research Company says the Pulmotech MAA market is set to expand through 2030 as lung disease rates rise, nuclear medicine use widens and imaging technology improves. North America held the largest market share in 2025, according to the report.

Why it matters: - Pulmotech MAA is used in lung scintigraphy to help diagnose pulmonary conditions, including pulmonary embolism. - Rising respiratory disease, chronic illness and an aging population are increasing demand for more precise pulmonary imaging. - The market’s growth could benefit hospitals, nuclear medicine providers and radiopharmaceutical suppliers as diagnostic use expands.

What happened: - The Business Research Company released a Pulmotech MAA market segmentation study on November 10, 2026. - The report says the market has grown on the back of more pulmonary embolism cases, broader hospital adoption of nuclear medicine, more technetium-based radiopharmaceuticals and more diagnostic imaging procedures. - The report says the market is expected to keep growing through 2030. - The company made the report available with a free sample and a full version.

The details: - Pulmotech MAA is a radiopharmaceutical used primarily in lung scintigraphy to evaluate pulmonary perfusion. - The product contains technetium Tc 99m-labeled aggregated human serum albumin particles. - After intravenous injection, the particles temporarily lodge in lung capillaries and help clinicians visualize blood flow in the lungs. - The report points to stronger demand for early and accurate pulmonary diagnostics, more investment in nuclear medicine infrastructure and more clinical research involving radiotracers. - It also highlights wider use of advanced lung perfusion imaging agents, more nuclear medicine use in pulmonary diagnostics and a focus on imaging accuracy and safety. - Respiratory disease incidence is a major growth driver because these conditions affect the lungs, airways and breathing muscles. - Environmental pollution, lifestyle habits, population aging and improved diagnostic methods are contributing to higher respiratory disease rates. - The Australian Institute of Health and Welfare reported in June 2024 that about 8.5 million Australians, or 34% of the population, had chronic respiratory conditions. - That same data set included 2.8 million people with asthma and 638,000 with chronic obstructive pulmonary disease. - Chronic disease growth is also supporting demand for precise pulmonary perfusion imaging. - Data published in April 2025 by the National Center for Health Statistics showed rising chronic disease prevalence among young and middle-aged adults in the U.S., including obesity, depression, diabetes and chronic kidney disease. - The Population Reference Bureau projected in January 2024 that the number of Americans age 65 and older will rise from 58 million in 2022 to 82 million by 2050. - That projection implies a 47% increase and a rise in the U.S. senior share of the population from 17% to 23%. - North America held the largest share of the Pulmotech MAA market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report frames Pulmotech MAA as part of a broader shift toward earlier diagnosis and more specialized imaging for chronic and age-related disease. - North America’s lead suggests the market is already tied to mature nuclear medicine infrastructure and established clinical adoption. - The report’s focus on forecasting tools, TAM analysis and market scoring signals that the company is pitching the study to investors and strategy teams as much as to clinicians.

What's next: - The report expects demand to rise as hospitals expand nuclear medicine capacity and clinicians seek more accurate pulmonary diagnostics. - Future growth will likely depend on imaging-agent innovation, infrastructure spending and continued uptake of lung perfusion studies. - The Business Research Company says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

The bottom line: - Pulmotech MAA is moving from a niche diagnostic tool to part of a broader growth market for pulmonary imaging, with aging populations and chronic disease prevalence doing much of the heavy lifting.